Literature DB >> 11994034

Genital herpes simplex virus infection in the adolescent: special considerations for management.

Lawrence R Stanberry1, Susan L Rosenthal.   

Abstract

Genital herpes simplex virus (HSV) infections are increasingly common among adolescents. In developed countries, during the 1990s, adolescent HSV type 2 seroprevalence rates ranged from 4 to 30% depending on the population studied. The clinical diagnosis of genital herpes may be unreliable and laboratory testing is recommended. Aciclovir, valaciclovir, and famciclovir are three antiviral drugs that have proven efficacy in the treatment of genital herpes. These drugs can be used in the treatment of the first episode or for recurrent infections, or can be used long term to suppress recurrent infections. Once or twice daily administration regimens are preferable for adolescents for reasons of adherence, and because it avoids the need to take medication at school. Unproven remedies are used commonly and can be harmful. In addition to antiviral therapy, proper management of the adolescent with genital herpes should also include developmentally appropriate explanations of the diagnosis, treatment and potential complications, recommendations for symptomatic relief, screening for other sexually transmitted infections, and discussion of safer sexual practices. All adolescents should have follow-up visits to complete education and counseling and to assess compliance with antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994034     DOI: 10.2165/00128072-200204050-00002

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  50 in total

1.  A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group.

Authors:  S L Spruance; S K Tyring; B DeGregorio; C Miller; K Beutner
Journal:  Arch Intern Med       Date:  1996 Aug 12-26

2.  A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group.

Authors:  A G Langenberg; L Corey; R L Ashley; W P Leong; S E Straus
Journal:  N Engl J Med       Date:  1999-11-04       Impact factor: 91.245

3.  Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group.

Authors:  N J Bodsworth; R J Crooks; S Borelli; G Vejlsgaard; J Paavonen; A M Worm; N Uexkull; J Esmann; A Strand; A J Ingamells; A Gibb
Journal:  Genitourin Med       Date:  1997-04

4.  Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial.

Authors:  R C Reichman; G J Badger; G J Mertz; L Corey; D D Richman; J D Connor; D Redfield; M C Savoia; M N Oxman; Y Bryson
Journal:  JAMA       Date:  1984-04-27       Impact factor: 56.272

5.  Prevalence of antibodies against varicella zoster, herpes simplex (types 1 and 2), hepatitis B and hepatitis A viruses among Spanish adolescents.

Authors:  A Gil; A González; R Dal-Ré; P Ortega; V Dominguez
Journal:  J Infect       Date:  1998-01       Impact factor: 6.072

6.  Seroprevalence of and risk factors for antibodies to herpes simplex viruses, hepatitis B, and hepatitis C among southwestern Hispanic and non-Hispanic white women.

Authors:  T M Becker; F Lee; J R Daling; A J Nahmias
Journal:  Sex Transm Dis       Date:  1996 Mar-Apr       Impact factor: 2.830

7.  Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group.

Authors:  M Reitano; S Tyring; W Lang; C Thoming; A M Worm; S Borelli; L O Chambers; J M Robinson; L Corey
Journal:  J Infect Dis       Date:  1998-09       Impact factor: 5.226

8.  Seroprevalence of herpes simplex virus type 2 antibodies in New Zealand sexual health clinic patients.

Authors:  N L Perkins; E P Coughlan; R A Franklin; M R Reid; J Taylor
Journal:  N Z Med J       Date:  1996-10-25

Review 9.  Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy.

Authors:  L Corey; J Benedetti; C Critchlow; G Mertz; J Douglas; K Fife; A Fahnlander; M L Remington; C Winter; J Dragavon
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790

Review 10.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

View more
  1 in total

1.  An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1.

Authors:  Julie L Dutton; Wai-Ping Woo; Janin Chandra; Yan Xu; Bo Li; Neil Finlayson; Paul Griffin; Ian H Frazer
Journal:  Hum Vaccin Immunother       Date:  2016-12       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.